IP Library Granted Patent US 8,143,249
Granted Patent B2
US 8,143,249 · App. 13/011,446 · Granted Mar 27, 2012

Prodrugs of A

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,143,249
App. No.
13/011,446
Granted
Mar 27, 2012
Kind
B2
Abstract

Disclosed are prodrugs of A 2B adenosine receptor antagonists of the formula: wherein R 1 and R 2 are independently lower alkyl; R 4 is optionally substituted phenyl; X is hydrogen or methyl; and Y is —C(O)R, in which R is optionally substituted aryl or optionally substituted heteroaryl or a pharmaceutically acceptable salt thereof, and their use in treating mammals for various disease states.

Claims (15)

1. A compound of the formula:

wherein:

R 1 and R 2 are independently lower alkyl;

R 4 is optionally substituted phenyl;

X is hydrogen or methyl; and

Y is —C(O)R, in which R is optionally substituted aryl or optionally substituted heteroaryl or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein R 1 and R 2 are independently ethyl or n-propyl.

3. The compound of claim 1 , wherein R 4 is 3-(trifluoromethyl)phenyl.

4. The compound of claim 3 , wherein R 1 is n-propyl and R 2 is ethyl.

5. The compound of claim 4 , wherein X is hydrogen.

6. A method of treating diarrhea in a mammal in need thereof, comprising administering to the mammal in need thereof a therapeutically effective dose of a compound of claim 1 .

7. A method of treating asthma in a mammal in need thereof, comprising administering to the mammal in need thereof a therapeutically effective dose of a compound of claim 1 .

8. A pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of claim 1 .

9. The compound of claim 5 , wherein R is phenyl or pyridyl.

10. The compound of claim 1 , selected from the group consisting of [3-ethyl-2,6-dioxo-1-propyl-8-(1-{[3-(trifluoromethyl)phenyl]methyl}pyrazol-4-yl)-1,3,7-trihydropurin-7-yl]methyl benzoate; [3-ethyl-2,6-dioxo-1-propyl-8-(1-{[3-(trifluoromethyl)phenyl]methyl}pyrazol-4-yl)-1,3,7-trihydropurin-7-yl]methyl 3-(trifluoromethyl)benzoate; [3-ethyl-2,6-dioxo-1-propyl-8-(1-{[3-(trifluoromethyl)phenyl]methyl}pyrazol-4-yl)-1,3,7-trihydropurin-7-yl]methyl 4-piperazinylbenzoate; [3-ethyl-2,6-dioxo-1-propyl-8-(1-{[3-(trifluoromethyl)phenyl]methyl}pyrazol-4-yl)-1,3,7-trihydropurin-7-yl]methyl 4-morpholin-4-ylbenzoate and [3-ethyl-2,6-dioxo-1-propyl-8-(1-{[3-(trifluoromethyl)phenyl]methyl}pyrazol-4-yl)-1,3,7-trihydropurin-7-yl]methylpyridine-3-carboxylate.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2011
From: GILEAD PALO ALTO, INC.
To: GILEAD SCIENCES, INC.
Reel/Frame 027077/0319 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2011
From: GILEAD PALO ALTO, INC.
To: GILEAD SCIENCES, INC.
Reel/Frame 025902/0018 →
MERGER Recorded Mar 1, 2011
From: CV THERAPEUTICS, INC.; APEX MERGER SUB, INC.
To: GILEAD PALO ALTO, INC.
Reel/Frame 025883/0013 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2011
From: KALLA, RAO; KOLTUN, DMITRY; ZABLOCKI, JEFF; ELZEIN, ELFATIH
To: CV THERAPEUTICS, INC.
Reel/Frame 025883/0029 →